US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Vericel Corporation - Common Stock (NQ:VCEL)

40.05 -1.02 (-2.48%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
From Wall Street Investor
Via GlobeNewswire
News headline image
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
From Vericel Corporation
Via GlobeNewswire
Vericel (NASDAQ:VCEL) Stands Out on the Affordable Growth Screen ↗
Via Chartmill
Vericel (NASDAQ:VCEL): A Strong Growth Play With an Improving Technical Setup ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Growth at a Reasonable Price ↗
Via Chartmill
News headline image
3 Major Earnings Winners You May Have Missed ↗
Vericel, Xenia Hotels & Resorts, and International Paper each posted Q2 2026 earnings with overlooked positives, from raised guidance to improved margins, despite mixed headline results. 
Via MarketBeat
Vericel (NASDAQ:VCEL) Beats Q2 Estimates, Raises Guidance, Shares Rise ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout Setup ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable Valuation ↗
Via Chartmill
News headline image
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
Vericel Q2 Earnings Call Highlights ↗
Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved... 
Via MarketBeat
Topics Earnings
Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotech ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Growth and Technical Setup Align for Potential Breakout ↗
Via Chartmill
Vericel (NASDAQ:VCEL) Balances High Growth and Reasonable Valuation in Affordable Growth Screen ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): A Prime Example of Affordable Growth ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Smashes Q1 Estimates, Raises Full-Year Outlook as MACI and Burn Care Surge ↗
Via Chartmill
News headline image
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests ↗
Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
From Biotech Insider
Via GlobeNewswire
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity ↗
Via Chartmill
News headline image
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
From World Street Intelligence
Via GlobeNewswire
News headline image
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MediWound (MDWD) Q1 2026 Earnings Transcript ↗
MediWound (MDWD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
From Energy Metal News
Via GlobeNewswire
News headline image
Vericel Q1 Earnings Call Highlights ↗
Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as... 
Via MarketBeat
Topics Earnings
News headline image
Vericel (VCEL) Q1 2026 Earnings Transcript ↗
Vericel (VCEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
From Vericel Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >